Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBL697 in Mild to Moderate Active Ulcerative Colitis
NCT04898348Phase 2Withdrawn
- Sponsor
- KoBioLabs
- Start
- Jan 2022
- Primary completion
- Jul 2023
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing KBL697 with Placebo (2 arms). Primary endpoint: Proportion of Patients with Clinical Remission at Week 8. Planned start Jan 2022; status: withdrawn.
02
Drugs
Lactobacillus gasseri KBL697
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04898348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898348.